Empiric Treatment of Community‐Acquired Pneumonia with Fluoroquinolones, and Delays in the Treatment of Tuberculosis
Open Access
- 15 June 2002
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 34 (12) , 1607-1612
Abstract
Fluoroquinolones, which are widely used to treat community-acquired pneumonia, also have excellent in vitro activity against Mycobacterium tuberculosKeywords
This publication has 19 references indexed in Scilit:
- Practice Guidelines for the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2000
- Evaluation of an Intensive Intermittent‐Induction Regimen and Duration of Short‐Course Treatment for Human Immunodeficiency Virus–Related Pulmonary TuberculosisClinical Infectious Diseases, 1998
- The Early Bactericidal Activity of Ciprofloxacin in Patients with Pulmonary TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 1997
- The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis1996
- Randomized Controlled Trial of a Drug Regimen That Includes Ciproftoxacin for the Treatment of Pulmonary TuberculosisClinical Infectious Diseases, 1996
- In-vitro activity of quinolones and macrolides against mycobacteriaJournal of Antimicrobial Chemotherapy, 1994
- Delayed diagnosis of pulmonary tuberculosis in city hospitalsArchives of internal medicine (1960), 1994
- The Use of Quinolones in Developing CountriesDrugs, 1993
- Comparative in-vitro activity of five fluoroquinolones against mycobacteriaJournal of Antimicrobial Chemotherapy, 1987
- In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosisJournal of Antimicrobial Chemotherapy, 1987